DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Emcure Pharmaceuticals Limited (EMCURE) share price today?

Emcure Pharmaceuticals Limited (EMCURE) is trading at ₹1,833.5 on the NSE, down 0.14% on the day. Source: DocStoX.

What is the PE ratio of Emcure Pharmaceuticals Limited?

Emcure Pharmaceuticals Limited has a price-to-earnings (PE) ratio of 37.6 in the Healthcare sector.

What is the market capitalisation of Emcure Pharmaceuticals Limited?

Emcure Pharmaceuticals Limited has a market capitalisation of approximately ₹34,586 crore.

Is Emcure Pharmaceuticals Limited a profitable company?

Emcure Pharmaceuticals Limited generates a return on equity of 18.7% with a net profit margin of 10.2%. That is a strong return on shareholder capital.

What is the 52-week high and low of EMCURE?

Emcure Pharmaceuticals Limited (EMCURE) has traded between ₹1,306.5 and ₹2,100.7 over the past 52 weeks, against a current price of ₹1,833.5.

Does Emcure Pharmaceuticals Limited pay a dividend?

Yes. Emcure Pharmaceuticals Limited currently offers a dividend yield of 0.18%. Dividend payments depend on the board's declaration each year.

Emcure Pharmaceuticals Limited

₹1,833.50▼ -2.50 (-0.14%)

EMCURE·NSE·Healthcare

Market Cap

34586.15 Cr

PE Ratio

37.59

Volume

21,412

Day High - Low

1849.30 - 1816.20

52W High-Low

2100.70 - 1306.50

₹1,833.50▼ -2.50 (-0.14%)

Market Cap34586.15 Cr

PE Ratio37.59

Volume21,412

Day High - Low1849.30 - 1816.20

52W High-Low2100.70 - 1306.50

Emcure Pharmaceuticals Limited (EMCURE): company summary

The company's business is improving, with annual revenue rising 16.6% and annual net profit growing 33.1%.

Emcure Pharmaceuticals Limited (EMCURE) is a mid-cap Healthcare company valued at ₹34,586 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Emcure Pharmaceuticals Limited last traded at ₹1,833.5, modestly down 0.14% on the day.
Recent developments: On 2026-08-06, the company reported a 36% rise in Q1 profit to ₹292.5 crore, with revenue from operations up 22.8% to ₹2,580.45 crore. The same day, the CEO was appointed as chairman. On 2026-07-23, the company completed a ₹232 crore buyout of the remaining 12.05% stake in Gennova Biopharma. On 2026-07-21, it received CDSCO approval to market Poviztra for MASH liver disease in India.
Financial performance: The company's business is improving, with annual revenue rising 16.6% and annual net profit growing 33.1%. The latest quarter saw revenue increase 22.8% compared to the same quarter a year earlier, and net profit rose 36.0%.
Valuation multiples: The stock trades at 37.6 times earnings, a premium to the Healthcare median of 32.0, 7.52 times book value. It yields 0.2%.
Things to watch: The stock is 12.7% below its 52-week high. Promoter shares pledged account for 0.04% of promoter holding. Foreign institutional holding increased by 1.53 percentage points in the quarter, while domestic institutional holding rose by 2.36 percentage points.
Where it stands: The company's latest quarter net profit rose 36.0% compared to the same quarter a year earlier, and annual net profit grew 33.1%. The stock is 12.7% below its 52-week high, and promoter shares pledged account for 0.04% of promoter holding.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

6.5/10

Fair

Fair Value

ROE

18.67%

Strong

P/E

37.59x

Expensive

Debt / Equity

0.31

Moderate

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

NIFTY 500NIFTY SMALLCAP 250

Day₹1816

₹1849

52W₹1307

₹2101

DocStoX take

Supported by risk (9.7) and growth (7.5), but held back by valuation (1.1). Risk looks strong at 9.7, but that is offset by valuation at 1.1. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

6.5

/10

Fair

Quality

Solid

ROE 18.7%

Valuation

Expensive

P/E 37.6×

Growth

Strong

Revenue +12.8% 5Y CAGR

Risk

Low risk

D/E 0.31

Momentum

Firm

66% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹1,834

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹34,586 Cr

52W High / Low

₹2101 / ₹1307

Dividend Yield

0.18%

Promoter Holding

77.83%

EPS (TTM)

₹48.77

Book Value

₹261.09

Key highlights

Profitable in all of the last 5 years
Capital works hard — ROCE 22%
Strong returns on equity (19%)
Valuation is weak (1.1/10)

4 Positives1 Watchout

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Emcure Pharmaceuticals Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Emcure Pharmaceuticals Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Emcure Pharmaceuticals Limited with peers

Emcure Pharmaceuticals Limited vs Sun Pharmaceutical Industries Limited Emcure Pharmaceuticals Limited vs Divi's Laboratories Limited Emcure Pharmaceuticals Limited vs Torrent Pharmaceuticals Limited Emcure Pharmaceuticals Limited vs Apollo Hospitals Enterprise Limited Emcure Pharmaceuticals Limited vs Zydus Lifesciences Limited Emcure Pharmaceuticals Limited vs Laurus Labs Limited

Related tools & concepts

Value Emcure Pharmaceuticals Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

EMCURE newsLatest coverage & filings Open screenerFilter the whole market